Saturday, 25 June 2022


Singapore's Prestige Biopharma inks MoU for co-development of COVID-19/Influenza vaccine

30 March 2022 | News

To accelerate the development of more effective and accessible vaccines

image credit- shutterstock

image credit- shutterstock

Singapore-based Prestige Biopharma and Vaxine have entered into a memorandum of understanding (MoU) to collaborate on the supply of Vaxine’s COVID-19 Vaccine, Covax-19 (also known as Spikogen) and on the co-development of COVID-19/influenza combo vaccine.

Vaxine has developed a state-of-the-art recombinant protein vaccine against COVID-19 that is manufactured using insect cells and includes Vaxine’s proprietary Advax polysaccharide adjuvant. This vaccine showed efficacy against infection by the Delta variant in Phase 3 clinical trials and already is in use in the Middle East.

In December 2021, the Australian Therapeutic Goods Administration (TGA) granted a provisional determination allowing an application to be lodged for a provisional approval for this COVID-19 vaccine. Regulatory submissions are similarly underway in many other countries in parallel.

Through this MoU, Prestige and Vaxine will be building a long-term vaccine partnership, initially focused on manufacturing and commercialization of Vaxine’s COVID-19 vaccine and then as Covid-19 enters an endemic phase development of a next generation COVID-19/influenza combo vaccine as well as other vaccine projects.

The MoU will bring together Prestige’s global scale vaccine manufacturing capacity & research expertise with Vaxine’s innovative vaccine technologies including its vaccines against COVID-19, seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, dengue, malaria, allergy and cancer.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account